Chromadex (NASDAQ:CDXC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and […]
from Google Trends https://ift.tt/2CJKFhr
COMMENTS